Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose
Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women
with Osteopenia Secondary to Corticosteroids
Phase:
Phase 1
Details
Lead Sponsor:
Nancy E. Lane, MD
Collaborators:
California Institute for Regenerative Medicine California Institute for Regenerative Medicine (CIRM)